Key result
Mitral valve replacement with a novel porcine bioprosthetic valve in 5 dogs maintained antithrombogenicity without thrombogenesis over 12 months, though mild regurgitation suggested limited durability.
Why the study?
Does mitral valve replacement with porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound maintain antithrombogenicity and durability in dogs?
Observational (n=5)
No
Does mitral valve replacement with porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound maintain antithrombogenicity and durability in dogs?
Answers are grounded in this paper and cite their sources.
Porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound maintained antithrombogenicity for 12 months in dogs without long-term anticoagulation, though structural durability may be limited.
This study evaluated the long-term clinical performance of newly developed porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound for mitral valve replacement (MVR) in dogs. Five beagle dogs underwent MVR using the porcine bioprosthetic valves during cardiopulmonary bypass. Antithrombotic drugs were administered only for one month after MVR. Six months after MVR, transvalvular regurgitation was not observed in all dogs, paravalvular leakage was seen only in one dog. Twelve months after MVR, mild transvalvular regurgitations were observed in two dogs. Although diastolic atrioventricular pressure gradient was increased gradually, no significant differences were observed. Pressure half-time and valve area were within normal ranges as the bioprosthetic value. There was no clinical symptom of the thrombosis and the thrombogenesis was not observed in the porcine bioprosthetic valve and the annulus in all dogs for twelve months after MVR. The clinical findings suggest that antithrombogenicity of the valves were maintained, though the duability might not be enough in the long-term period.
No takes yet. Share an insight, caveat, or question.
TAKASHIMA et al. (2008) conducted an observational in Mitral valve replacement (experimental model) (n=5). Mitral valve replacement with porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound was evaluated on Long-term clinical performance including echocardiographic and hemodynamic parameters at 12 months. Mitral valve replacement with a novel porcine bioprosthetic valve in 5 dogs maintained antithrombogenicity without thrombogenesis over 12 months, though mild regurgitation suggested limited durability.
Synapse has enriched 10 related papers. Consider them for comparative context: